Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Enterprise Value (2016 - 2025)

Cardiff Oncology's Enterprise Value history spans 15 years, with the latest figure at -$17.5 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 80.96% year-over-year to -$17.5 million; the TTM value through Dec 2025 reached -$17.5 million, up 80.96%, while the annual FY2025 figure was -$17.5 million, 80.96% up from the prior year.
  • Enterprise Value for Q4 2025 was -$17.5 million at Cardiff Oncology, down from -$10.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$10.1 million in Q3 2025 and bottomed at -$140.8 million in Q4 2021.
  • The 5-year median for Enterprise Value is -$41.6 million (2024), against an average of -$59.4 million.
  • The largest annual shift saw Enterprise Value tumbled 1253.71% in 2021 before it soared 88.39% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$140.8 million in 2021, then increased by 25.25% to -$105.3 million in 2022, then grew by 28.92% to -$74.8 million in 2023, then decreased by 22.62% to -$91.7 million in 2024, then soared by 80.96% to -$17.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Enterprise Value are -$17.5 million (Q4 2025), -$10.1 million (Q3 2025), and -$10.8 million (Q2 2025).